BOSTON and NEW YORK, April 14, 2025 /PRNewswire/ -- Satio and Nanowear have agreed to partner to advance patient-friendly, home-based diagnostic, and therapeutic care. This collaboration integrates Nanowear's at-home AI-based nanotechnology biomarker diagnostic platform with Satio's at-home blood draw diagnostics and drug delivery systems/patches: combining time synchronous, in vivo and in vitro diagnostics for precision therapeutics and individualized AI-based risk assessment.
Since 2019, patients, healthcare systems, pharmaceutical companies, medtech firms, and direct-to-consumer (DTC) clinical trials have increasingly adopted home-based digital care. However, widespread adoption has been hindered by challenges in accuracy, reliability, cost, workflow integration, and limited access to actionable data and interoperability. These barriers have led to frustration and underutilization, highlighting the urgent need for more seamless and effective solutions in remote healthcare.
Nanowear is transforming home-based cardiometabolic healthcare with end-to-end FDA approved cloth nanotechnology and AI diagnostics, SimpleSense™, delivering a full cardiometabolic assessment and continuous picture of individualized health through the use of an AI digital diagnostic platform, while the patient is in the comfort of their own home. The SimpleSense™ platform simultaneously and time synchronously collects 85+ clinically validated cardiopulmonary and hemodynamic biomarkers, replacing first line diagnostic tools such as the continuous blood pressure line, digital stethoscope, multi-channel ECG, hemodynamic, spirometer, actigraphy monitors as well as continuous glucose monitoring (CGM) via a recently announced CGM integration and data partnership.
Satio, which recently had its remotely controlled drug delivery telemedicine episode recognized as the first Advanced Research Projects Agency for Health ARPA-H Small Business Innovation Research contract to be completed, enables decentralized care by transforming workflow with its patch-based adhesive technology to shift care from clinics to the home for blood-based diagnostics and drug delivery procedures. This partnership allows Satio's decentralization efforts to be accelerated with cutting-edge robust information capture and analytics.
Nanowear and Satio are exploring multiple collaboration pathways to revolutionize home-based diagnostics and care. One initiative focuses on integrating Satio's SatioDot dry blood spot and SatioDraw whole blood draw in vitro patches with Nanowear's SimpleSense system. This novel combination — merging blood and genotype biomarkers with cardiometabolic physiological data within a single digital app — marks a first-of-its-kind advancement in biopharma, pharmaceutical, medtech, and biotech clinical research, a market valued at approximately $55 billion annually. In a complementary approach, Nanowear's SimpleSense biomarkers would be incorporated into SatioRx's telehealth drug delivery system, enabling dynamic reporting and next-generation home-based care in a ~$200 billion total addressable market. Additionally, Nanowear and Satio will jointly promote their technologies and combined capabilities to key stakeholders, further accelerating innovation in digital healthcare.
"We are excited about the opportunities to merge in vitro and in vivo results and to enhance chronic disease, cardiometabolic and cancer drug delivery," says Namal Nawana, Chairman and Founder of Satio, "And as I've seen in diagnostics and orthopedics, shifting care away from brick and mortar requires not just disrupting workflow, but ensuring information flow is enhanced. This partnership will help ensure the patient's ease of mind and the clinician's decision-making are strengthened, not thrown into doubt."
"Our genes, blood, heart, lungs, vasculature, hemodynamic, and metabolic systems all talk to each other in very specific ways from patient to patient," says Venk Varadan, CEO and Co-founder of Nanowear. "This collaboration of the technologies that combine these key determinants of human health, result in a first-of-its-kind platform that will truly unlock early diagnosis and precision medicine."
"Precision medicine, individualized risk assessment, early diagnosis, home-based care… these were big buzz words that helped frame the digital health landscape post 2020 pandemic. What's been holding these capabilities back is the inability to time synchronously combine all of the relevant biomarkers that are individual to our unique bodies. When all of the health determinant biomarkers are available through a single data fire hose, AI precision medicine will make us healthier and save our healthcare system trillions."
Satio products are not yet approved for use in the US or other territories.
ABOUT NANOWEAR, INC
Nanowear is a leading healthcare-at-home digital diagnostics company providing a smarter way to collect and analyze cardiometabolic health through real-world evidence. Its nanotechnology sensors coupled with its end-to-end software, mobile, and AI-powered platform is a radical leap forward in clinical research and virtual care, empowering physician decision-making with scored, clinical-grade diagnostics through patented nanotechnology and AI diagnostics ultimately providing early diagnosis and precision medicine. To learn more, visit www.nanowearinc.com
ABOUT SATIO, INC
Satio is on a mission to decentralize healthcare by transforming workflow – in diagnostics, medicine delivery, and streamlined patient-provider interactions through deployment of connecting technologies and biometrics. Through this mission, Satio endeavors to make people healthier while decreasing costs and burdens. Satio is a privately held medical device company focused on point-of-need adhesive patches developing three different platforms. The first, SatioRx, is a reusable drug delivery platform to enable stable and controlled delivery of liquid medicines intradermally or subcutaneously. The second platform is dry blood spot (SatioDotTM) and whole blood sampling (SatioDrawTM) patches that facilitate home-use for a wide variety of lab-based and genomic testing. Those two diagnostics products are in late-stage clinical development. The third, SatioDxTM, is a consumer-based patch for direct testing, including results on-board the device in real time.
"The SatioDx project has been funded in whole or part with Federal funds from The Advanced Research Projects Agency for Health (ARPA-H), Department of Health and Human Services, under Contract No. 75N91023C00059 September 29, 2023."
SOURCE Satio
Share this article